• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunome Inc (NQ: IMNM )

    12.97 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immunome Inc

    < Previous 1 2 3 4 5 6 Next >
    Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
    From Immunome, Inc.
    Via Business Wire
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
    From Immunome, Inc.
    Via Business Wire
    Evaluating Immunome: Insights From 4 Financial Analysts
    Via Benzinga
    Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
    From Immunome, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Immunome Appoints Roee Shahar as Executive Vice President, Commercial
    From Immunome, Inc.
    Via Business Wire
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Immunome, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
    From Immunome, Inc.
    Via Business Wire
    Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    Immunome Stock Sees RS Rating Jump To 91
    Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
    Via Investor's Business Daily
    IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
    IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
    From Immunome, Inc.
    Via Business Wire
    Immunome Appoints Phil Tsai as Chief Technical Officer
    From Immunome, Inc.
    Via Business Wire
    Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immunome Announces Completion of Purchase of Assets from Atreca
    From Immunome, Inc.
    Via Business Wire
    Immunome Announces Promotion of Max Rosett to Chief Financial Officer
    From Immunome, Inc.
    Via Business Wire
    IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
    IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    Immunome to Present at 2024 Bank of America Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    Immunome Appoints Kinney Horn as Chief Business Officer
    From Immunome, Inc.
    Via Business Wire
    Immunome Appoints Sandra M. Swain to Board of Directors
    From Immunome
    Via Business Wire
    Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Immunome, Inc.
    Via Business Wire
    IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
    IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
    From Immunome, Inc.
    Via Business Wire
    Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
    In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.